Compare CDXS & NUW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CDXS | NUW |
|---|---|---|
| Founded | 2002 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Investment Managers |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 256.3M | 251.7M |
| IPO Year | 2008 | 2008 |
| Metric | CDXS | NUW |
|---|---|---|
| Price | $2.79 | $13.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 910.5K | 60.8K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.82 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $138,590,000.00 | N/A |
| Revenue This Year | $7.73 | N/A |
| Revenue Next Year | $14.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 32.30 | N/A |
| 52 Week Low | $0.96 | $13.50 |
| 52 Week High | $3.87 | $14.70 |
| Indicator | CDXS | NUW |
|---|---|---|
| Relative Strength Index (RSI) | 59.28 | 44.34 |
| Support Level | $2.39 | $13.87 |
| Resistance Level | $2.87 | $14.51 |
| Average True Range (ATR) | 0.15 | 0.16 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 79.28 | 32.00 |
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
Nuveen AMT-Free Municipal Value Fund is a diversified closed-end management investment company. The Fund's primary investment objective is to provide current income exempt from regular federal income tax. The Fund's secondary investment objective is to enhance portfolio value and total return.